Pharma Focus Asia

Kaken Pharmaceutical signs agreement with Dong-A ST for Clenafin/Jublia in Korea

Tuesday, May 31, 2016

Kaken Pharmaceutical Co Ltd :

Says Kaken Pharmaceutical and A Korea-based firm Dong-A ST Co Ltd concluded an exclusive distribution agreement for the topical formulation for Onychomycosis "Clenafin / Jublia" in Korea.

Says according to the agreement, Kaken hereby grant to Dong-A the exclusive right for development and sales of the Product in Korea.

 

Source : reuters.com

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024